Nuformix hosting online Q&A session on 13 June 2023

Nuformix plc

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that the Company’s Executive Director, Dr Dan Gooding, will be hosting an online Q&A session at 5.30 p.m. GMT on Tuesday 13 June 2023.  This session is open to all existing and prospective shareholders.  Those who wish to attend should register via the following link where they will be provided with access details:

https://us02web.zoom.us/webinar/register/WN_fV_2UztcQLSl1S1tC4vTGg

Participants will have the opportunity to submit questions during the session, but questions are welcomed in advance and may be submitted to: [email protected]

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Nuformix to acquire Biovara in deal to combine two respiratory drug programmes

Nuformix has agreed heads of terms to acquire Biovara Limited in a proposed share-for-share deal, adding its LipAprep treatment...

Nuformix reports further positive NXP002 results demonstrating TGF-β pathway modulation

Nuformix plc reports statistically significant reductions in TGF-β/SMAD signalling following inhaled administration of NXP002 in a preclinical study, supporting...

Nuformix Dr Dan Gooding on positive NXP002 study results and next steps

Nuformix says new preclinical results for inhaled NXP002 support its development as a potential treatment for idiopathic pulmonary fibrosis,...

Nuformix appoints Tim Metcalfe as Non-Executive Chairman

Nuformix has appointed Tim Metcalfe as non-executive chairman, with Julian Gilbert stepping down from the board for personal reasons....

Nuformix adds new preclinical support for NXP002

Nuformix has reported encouraging inhalation data for NXP002 as it prepares for further preclinical development and potential licensing discussions....

Nuformix Plc NXP002 Data Strengthens Path Towards Toxicology and Partnering (video)

Dr Dan Gooding discusses therapeutically relevant lung exposure, fibrosis-related pathway engagement, the potential therapeutic window, toxicology planning and the...

Search